Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefoperazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 0.88 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.88 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.88 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.88 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.87 |
| ▸ | THRB | P10828 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | POLB | P06746 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11089531 | 0.94 | TDP1 (0.90) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| SCHEMBL11083504 | 0.94 | TDP1 (0.90) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| Cefoperazone SCHEMBL6655255 | 0.94 | MAPT (0.99) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| Cefoperazone SCHEMBL11522109 | 0.94 | MAPT (1.00) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| Cefoperazone SCHEMBL18061225 | 0.94 | MAPT (1.00) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| Cefoperazone SCHEMBL16072819 | 0.94 | MAPT (1.00) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| Cefoperazone SCHEMBL15387468 | 0.94 | MAPT (1.00) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| Cefoperazone SCHEMBL2222952 | 0.94 | MAPT (1.00) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| Cefoperazone SCHEMBL16091123 | 0.94 | MAPT (1.00) | TDP1MAPTSLC22A6SLC22A8SLC22A11 | |
| Cefoperazone SCHEMBL9326569 | 0.94 | MAPT (1.00) | TDP1MAPTSLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116687867-A | Cefoperazone sodium for injection and preparation method thereof | 南京恩泰医药科技有限公司 | 2023-09-05 | — | — | CN | claimed |
| US-9227999-B2 | Antimicrobial cationic peptides and formulations thereof | CARRUS CAPITAL CORPORATION (CA) | 2016-01-05 | — | — | US | claimed |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-3866826-B1 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING THE SAME | RIPTIDE BIOSCIENCE INC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | GREGG JOHN M H (US) | 2025-04-29 | — | — | US | disclosed |
| CN-119818504-A | Antibacterial composition of cefoperazone and avibactam and application thereof | 重庆圣华曦药业股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113861268-B | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250099566-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | NATIONAL INSTITUTES OF HEALTH | 2025-03-27 | — | — | US | disclosed |
| WO-2025059113-A1 | TREATMENTS FOR ENHANCING IMMUNE RESPONSE TO CLOSTRIDIOIDES DIFFICILE INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119391643-B | Culture medium and method for culturing digestive tract tumor by using three-dimensional tumor tablet technology | 珠海澳大科技研究院 | 2025-03-14 | — | — | CN | disclosed |
| EP-0925308-B1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH INC (CA) | 2002-06-05 | — | — | EP | disclosed |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | BIOWEST THERAPEUTICS INC. (CA) | 2002-03-21 | — | — | US | disclosed |
| EP-1174439-A2 | Compositions and methods for treating infections using analogues of indolicidin | Micrologix Biotech, Inc. (CA) | 2002-01-23 | — | — | EP | disclosed |
| US-6180604-B1 | Compositions and methods for treating infections using analogues of indolicidin | MICROLOGIX BIOTECH INC. (CA) | 2001-01-30 | — | — | US | disclosed |
| EP-0966481-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 1999-12-29 | — | — | EP | disclosed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998040401-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | MICROLOGIX BIOTECH INC. (CA) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998007745-A9 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | — | 1998-04-23 | — | — | WO | disclosed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | TDP1 236/4885MAPT 2164/4885SLC22A6 305/4885 |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | ACE2, ACE, MAVS | TDP1 2443/4885MAPT 2631/4885SLC22A6 942/4885 |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | VIP, PEPD, PTMS | TDP1 3303/4885MAPT 2784/4885SLC22A6 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.